The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase II/III clinical trials for Renal Cell Cancer and an interim analysis is planned for mid 2008.
The following items were presented at the American Association for Cancer Research meeting in San Diego.
A biomarker that may help doctors monitor the effectiveness of common treatments for kidney cancer and non-small cell lung cancer has been identified by researchers in the Netherlands.
Bill Wondergem, 21, a Calvin biology major and biochemistry minor, has worked since his junior year as an intern in the lab of Bin Teh, a distinguished scientific investigator at the Van Andel Research Institute (VARI) and a specialist in kidney cancer.
These products have also been linked to an increased risk of kidney cancer in people who have consumed them.
Showed a 54 percent regression of the tumor volume.
Shows Tumor Regression in Patients with Advanced Renal Cancer.
Early Data on Amgens Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types
Amgen today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors -- bevacizumab or motesanib diphosphate (AMG 706) -- compared with either treatment alone (p< 0.05).
Alpha Tau Omega of the University of California Santa Barbara presents All Sorority Volleyball Tournament 2008
Volleyball tournament raises thousands for kidney cancer!!
SGN-75 is an antibody-drug conjugate (ADC) that has demonstrated potent antitumor activity at well-tolerated doses in preclinical models of renal cell cancer.